Teneligliptin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Teneligliptin
Accession Number
DB11950
Type
Small Molecule
Groups
Investigational
Description

Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.

Structure
Thumb
Synonyms
Not Available
External IDs
MP-513
Categories
UNII
28ZHI4CF9C
CAS number
760937-92-6
Weight
Average: 426.578
Monoisotopic: 426.220180302
Chemical Formula
C22H30N6OS
InChI Key
WGRQANOPCQRCME-PMACEKPBSA-N
InChI
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
IUPAC Name
1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-4-[(3S,5S)-5-(1,3-thiazolidine-3-carbonyl)pyrrolidin-3-yl]piperazine
SMILES
[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when 2,4-thiazolidinedione is combined with Teneligliptin.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Teneligliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Teneligliptin.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Teneligliptin.
AcebutololThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Acetazolamide.
AcetohexamideTeneligliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Teneligliptin.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Teneligliptin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11949652
PubChem Substance
347828276
ChemSpider
10123963
BindingDB
50391565
ChEBI
136042
ChEMBL
CHEMBL2147777
ZINC
ZINC000036520254
PDBe Ligand
M51
Wikipedia
Teneligliptin
PDB Entries
3vjk

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherDiabete Mellitus1
1CompletedOtherHealthy Volunteers2
1CompletedTreatmentDiabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus2
3CompletedTreatmentType 2 Diabetes Mellitus13
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentType2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus2
Not AvailableRecruitingNot AvailableType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP1.69ALOGPS
logP1.42ChemAxon
logS-2.5ALOGPS
pKa (Strongest Basic)9.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.64 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.78 m3·mol-1ChemAxon
Polarizability46.91 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid amides
Alternative Parents
N-arylpiperazines / Phenylpyrazoles / Dialkylarylamines / Pyrrolidinecarboxamides / N-alkylpiperazines / Benzene and substituted derivatives / Heteroaromatic compounds / Tertiary carboxylic acid amides / Thiazolidines / Trialkylamines
show 7 more
Substituents
Alpha-amino acid amide / N-arylpiperazine / Phenylpyrazole / Pyrrolidine-2-carboxamide / Pyrrolidine carboxylic acid or derivatives / Dialkylarylamine / N-alkylpiperazine / Monocyclic benzene moiety / Benzenoid / Piperazine
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:03 / Updated on March 01, 2020 21:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates